High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy

Hayato Fujita, Kenoki Ohchida, Kazuhiro Mizumoto, Soichi Itaba, Tetsuhide Ito, Kohei Nakata, Jun Yu, Tadashi Kayashima, Akifumi Hayashi, Ryota Souzaki, Tatsuro Tajiri, Manabu Onimaru, Tatsuya Manabe, Takao OHTSuka, Masao Tanaka

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/EGFR) targeting agent presented a significant benefit compared to treatment with gemcitabine alone. The aim of this study was to investigate EGFR mRNA expression in resected PDAC tissues and its correlation with patient prognosis. We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 88 patients with PDAC who underwent pancreatectomy, and measured EGFR mRNA levels by quantitative real-time reverse transcription-polymerase chain reaction. The high-level EGFR group had significantly shorter disease-free-survival (p=0.029) and overall-survival (p=0.014) as shown by univariate analyses, although these did not reach statistical significance, as shown by multivariate analyses. However, we found that high EGFR expression was an independent prognostic factor in patients receiving gemcitabine-based adjuvant chemotherapy (p=0.023). Furthermore, we measured EGFR mRNA levels in 20 endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytological specimens. Altered EGFR levels were distinguishable in microdissected neoplastic cells from EUS-FNA cytological specimens compared to those in whole cell pellets. In conclusion, quantitative analysis of EGFR mRNA expression using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytological specimens could be useful in predicting prognosis and sensitivity to gemcitabine in PDAC patients.

Original languageEnglish
Pages (from-to)629-641
Number of pages13
JournalInternational journal of oncology
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 1 2011

Fingerprint

gemcitabine
Endoscopic Ultrasound-Guided Fine Needle Aspiration
Adjuvant Chemotherapy
Pancreatic Neoplasms
Adenocarcinoma
Messenger RNA
Survival
Paraffin
Formaldehyde
Phase III Clinical Trials
Pancreatectomy
Epidermal Growth Factor Receptor
Reverse Transcription
Disease-Free Survival
Multivariate Analysis
Polymerase Chain Reaction
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. / Fujita, Hayato; Ohchida, Kenoki; Mizumoto, Kazuhiro; Itaba, Soichi; Ito, Tetsuhide; Nakata, Kohei; Yu, Jun; Kayashima, Tadashi; Hayashi, Akifumi; Souzaki, Ryota; Tajiri, Tatsuro; Onimaru, Manabu; Manabe, Tatsuya; OHTSuka, Takao; Tanaka, Masao.

In: International journal of oncology, Vol. 38, No. 3, 01.03.2011, p. 629-641.

Research output: Contribution to journalArticle

Fujita, Hayato ; Ohchida, Kenoki ; Mizumoto, Kazuhiro ; Itaba, Soichi ; Ito, Tetsuhide ; Nakata, Kohei ; Yu, Jun ; Kayashima, Tadashi ; Hayashi, Akifumi ; Souzaki, Ryota ; Tajiri, Tatsuro ; Onimaru, Manabu ; Manabe, Tatsuya ; OHTSuka, Takao ; Tanaka, Masao. / High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. In: International journal of oncology. 2011 ; Vol. 38, No. 3. pp. 629-641.
@article{4a553d854e854e029c16e56057fb78c7,
title = "High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/EGFR) targeting agent presented a significant benefit compared to treatment with gemcitabine alone. The aim of this study was to investigate EGFR mRNA expression in resected PDAC tissues and its correlation with patient prognosis. We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 88 patients with PDAC who underwent pancreatectomy, and measured EGFR mRNA levels by quantitative real-time reverse transcription-polymerase chain reaction. The high-level EGFR group had significantly shorter disease-free-survival (p=0.029) and overall-survival (p=0.014) as shown by univariate analyses, although these did not reach statistical significance, as shown by multivariate analyses. However, we found that high EGFR expression was an independent prognostic factor in patients receiving gemcitabine-based adjuvant chemotherapy (p=0.023). Furthermore, we measured EGFR mRNA levels in 20 endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytological specimens. Altered EGFR levels were distinguishable in microdissected neoplastic cells from EUS-FNA cytological specimens compared to those in whole cell pellets. In conclusion, quantitative analysis of EGFR mRNA expression using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytological specimens could be useful in predicting prognosis and sensitivity to gemcitabine in PDAC patients.",
author = "Hayato Fujita and Kenoki Ohchida and Kazuhiro Mizumoto and Soichi Itaba and Tetsuhide Ito and Kohei Nakata and Jun Yu and Tadashi Kayashima and Akifumi Hayashi and Ryota Souzaki and Tatsuro Tajiri and Manabu Onimaru and Tatsuya Manabe and Takao OHTSuka and Masao Tanaka",
year = "2011",
month = "3",
day = "1",
doi = "10.3892/ijo.2011.908",
language = "English",
volume = "38",
pages = "629--641",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy

AU - Fujita, Hayato

AU - Ohchida, Kenoki

AU - Mizumoto, Kazuhiro

AU - Itaba, Soichi

AU - Ito, Tetsuhide

AU - Nakata, Kohei

AU - Yu, Jun

AU - Kayashima, Tadashi

AU - Hayashi, Akifumi

AU - Souzaki, Ryota

AU - Tajiri, Tatsuro

AU - Onimaru, Manabu

AU - Manabe, Tatsuya

AU - OHTSuka, Takao

AU - Tanaka, Masao

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/EGFR) targeting agent presented a significant benefit compared to treatment with gemcitabine alone. The aim of this study was to investigate EGFR mRNA expression in resected PDAC tissues and its correlation with patient prognosis. We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 88 patients with PDAC who underwent pancreatectomy, and measured EGFR mRNA levels by quantitative real-time reverse transcription-polymerase chain reaction. The high-level EGFR group had significantly shorter disease-free-survival (p=0.029) and overall-survival (p=0.014) as shown by univariate analyses, although these did not reach statistical significance, as shown by multivariate analyses. However, we found that high EGFR expression was an independent prognostic factor in patients receiving gemcitabine-based adjuvant chemotherapy (p=0.023). Furthermore, we measured EGFR mRNA levels in 20 endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytological specimens. Altered EGFR levels were distinguishable in microdissected neoplastic cells from EUS-FNA cytological specimens compared to those in whole cell pellets. In conclusion, quantitative analysis of EGFR mRNA expression using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytological specimens could be useful in predicting prognosis and sensitivity to gemcitabine in PDAC patients.

AB - Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/EGFR) targeting agent presented a significant benefit compared to treatment with gemcitabine alone. The aim of this study was to investigate EGFR mRNA expression in resected PDAC tissues and its correlation with patient prognosis. We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 88 patients with PDAC who underwent pancreatectomy, and measured EGFR mRNA levels by quantitative real-time reverse transcription-polymerase chain reaction. The high-level EGFR group had significantly shorter disease-free-survival (p=0.029) and overall-survival (p=0.014) as shown by univariate analyses, although these did not reach statistical significance, as shown by multivariate analyses. However, we found that high EGFR expression was an independent prognostic factor in patients receiving gemcitabine-based adjuvant chemotherapy (p=0.023). Furthermore, we measured EGFR mRNA levels in 20 endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytological specimens. Altered EGFR levels were distinguishable in microdissected neoplastic cells from EUS-FNA cytological specimens compared to those in whole cell pellets. In conclusion, quantitative analysis of EGFR mRNA expression using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytological specimens could be useful in predicting prognosis and sensitivity to gemcitabine in PDAC patients.

UR - http://www.scopus.com/inward/record.url?scp=79952022235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952022235&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.908

DO - 10.3892/ijo.2011.908

M3 - Article

C2 - 21243324

AN - SCOPUS:79952022235

VL - 38

SP - 629

EP - 641

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -